The Man Who Couldn’t Lose Weight
John is 43 years old, lives in Ohio, and carries more weight than he wants to.
There is nothing particularly unusual about him. He works long hours in a sedentary office job. Most of his day is spent sitting—at a desk, in a car, or in front of a screen. By the time he gets home, he is tired, not energized. Cooking feels like effort. Exercise feels like another obligation.
So he does what millions of people do. He eats what is available, affordable, and convenient.
Cheap calories are everywhere. Processed food is engineered to taste better, last longer, and cost less. Advertising follows him relentlessly—on his phone, on billboards, on television—nudging him toward food that is high in sugar, fat, and salt. Not because it is good for him, but because it is profitable.
John has tried to fight back.
He has dieted. He has joined a gym. He has made promises to himself—start walking to work, cut down on junk food, be more disciplined. For a few weeks, sometimes even a few months, it works. The scale moves. Progress feels real.
Then life catches up.
Work gets busy. Energy dips. Habits slip. The weight returns, often faster than it left. Each attempt feels harder than the last, not because John is weaker, but because the system around him has not changed.
And so, eventually, something shifts—not in his body, but in his expectations.
He stops believing this is a problem he can solve.
He starts believing this is just how life is.
John is not alone. In the United States, more than 75% of adults are overweight or obese. What was once an exception has become the norm. Entire populations now live in environments where gaining weight is easier than losing it, and where staying healthy requires constant resistance against the structure of everyday life.
This is what makes obesity feel inevitable. Not because individuals have stopped caring, but because the conditions they live in make success statistically unlikely.
For decades, the solutions have been predictable.
Eat less. Move more. Try harder.
Public health campaigns repeat the message. Fitness industries monetize it. Diet programs repackage it. And yet, at scale, it has failed. Not completely, but consistently enough that the broader trend has only moved in one direction.
Which is why something unusual is happening now.
For the first time, there is a class of drugs that does not ask John to fight his environment harder.
Instead, it changes how his body responds to that environment.
Drugs like Ozempic are not just helping people lose weight. They are doing something far more disruptive: they are making weight loss achievable at scale, in the same world where it once felt impossible.
And if that holds true, then the implications go far beyond John.
They reach into the way entire societies eat, spend, work, and live.
The First Drug That Actually Works at Scale
For decades, the weight-loss industry has operated on a simple premise: if enough people try hard enough, they will eventually succeed.
The problem is that, at scale, they don’t.
Diets work—until they don’t. Gym memberships spike every January and fade by March. Public health campaigns raise awareness, but rarely change long-term behavior. The entire system is built on individual effort, and individual effort is notoriously fragile when it has to fight biology, environment, and routine at the same time.
This is what makes GLP-1 drugs fundamentally different.
They are not another attempt to motivate people into eating less. They change the conditions under which eating decisions are made in the first place.
Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound belong to a class known as GLP-1 receptor agonists. That name is technical, but their impact is simple: they make it easier to eat less without constantly thinking about it.
And unlike previous weight-loss interventions, the results are not marginal.
In clinical trials, patients taking semaglutide—the active compound in Ozempic—lost nearly 15% of their body weight over roughly a year. The placebo group, by contrast, lost only around 2–3%. That gap is not incremental. It is transformative.
To put it differently, this is not the difference between trying harder and trying a little harder. It is the difference between fighting your body every day and having your body quietly cooperate.
That is why these drugs have generated so much attention—not just in medicine, but across industries.
Because if you zoom out, obesity is not a niche problem. In the United States alone, more than 40% of adults are clinically obese. Globally, the numbers are rising across both developed and developing economies. The potential market is not millions of people—it is hundreds of millions.
And yet, only a small fraction of that population is currently being treated.
Despite this, the demand has already been explosive. GLP-1 drugs have become some of the fastest-growing pharmaceutical products in history. Companies like Novo Nordisk and Eli Lilly are not just benefiting—they are being reshaped by it. In Denmark, Novo Nordisk has grown so large that it now plays a meaningful role in the national economy itself.
This is what scale looks like.
Not a niche treatment for a small group of patients, but a product with the potential to alter population-level outcomes.
And that is the real break from the past.
Previous solutions relied on behavior change spreading slowly, unevenly, and often unsuccessfully across society. GLP-1 drugs, by contrast, offer something closer to a technological shortcut—an intervention that can produce consistent results across millions of people, regardless of how chaotic or unhealthy their environment may be.
For the first time, weight loss is no longer entirely dependent on willpower.
And once that constraint is removed, the question is no longer whether people can lose weight.
It is what happens when millions of them suddenly do.
How Ozempic Rewires the Body
To understand why these drugs are so effective, you have to move away from the idea that they simply “help people eat less.”
That’s true—but it misses the mechanism that makes them powerful.
GLP-1 drugs like Ozempic mimic a hormone your body already produces: glucagon-like peptide-1. Under normal conditions, this hormone is released in your gut after you eat. It signals to your brain that you are full, regulates blood sugar, and helps coordinate how your body processes energy.
What these drugs do is amplify that signal—and make it persistent.
The first effect is mechanical. Food moves more slowly from the stomach into the intestine. That delay keeps you feeling full for longer after each meal. The urge to snack weakens, not because you are resisting it, but because it simply doesn’t arise with the same intensity.
The second effect is metabolic. GLP-1 drugs reduce the production of glucagon, a hormone that raises blood sugar levels. By smoothing out these spikes, they reduce the sharp fluctuations that often trigger hunger and cravings. The constant cycle of “eat, spike, crash, crave” becomes less pronounced.
The third effect is hormonal. They stimulate insulin production, making it easier for the body to use glucose efficiently and burn energy more effectively. Over time, this shifts the body into a state where fat loss is more achievable, not just theoretically, but practically.
But the most important effect is psychological—though it doesn’t feel like psychology.
People on these drugs often report something unusual. They don’t feel like they are dieting. They are not constantly negotiating with themselves about food. The background noise—the mental chatter about what to eat, when to eat, whether to eat—quiets down.
Hunger becomes less urgent. Cravings become less persuasive.
And when that happens, behavior changes almost automatically.
In one study, patients reduced their daily calorie intake by roughly 25%—around 700 to 750 calories per day—without being instructed to follow a strict diet. That is not a small adjustment. That is the kind of reduction that, sustained over time, produces significant weight loss.
This is why these drugs feel different from everything that came before.
They do not rely on discipline in the traditional sense. They do not ask people to override their instincts every day. Instead, they subtly reshape those instincts so that eating less feels natural rather than forced.
And when you scale that across millions of people, the implications extend far beyond individual health.
Because if people are not just trying to eat less—but actually wanting less—then the ripple effects start to spread outward.
From the body… to behavior… to the economy itself.
From Appetite to Economy
At the individual level, the story is straightforward.
People feel less hungry. They eat less. Over time, they lose weight.
But scale that across millions of people, and something more interesting begins to happen.
Because eating is not just a biological act—it is an economic one.
Every calorie consumed is tied to a purchase. Every snack, every meal, every impulse buy at a checkout counter feeds into a vast network of industries built around one simple assumption: people will keep eating more.
GLP-1 drugs quietly challenge that assumption.
When patients reduce their daily calorie intake by 20–25%, they are not just changing what they eat. They are changing how much they spend. Fewer snacks. Smaller portions. Less frequent indulgence. The shift is subtle at first, almost invisible at the level of a single person.
But across tens of millions of people, it compounds.
Analysts are already trying to quantify what this looks like. In the United States alone, the number of people using GLP-1 drugs is expected to more than double over the next decade. That means tens of millions of consumers whose relationship with food is being recalibrated at the biological level.
And when demand changes at that scale, supply has to respond.
This is where the idea of “low-calorie capitalism” begins to take shape.
An economy that has spent decades optimizing for higher consumption—bigger portions, more frequent eating, hyper-palatable foods—suddenly encounters a population that, quite literally, wants less.
Less food. Less snacking. Less excess.
That does not just affect grocery bills. It begins to ripple outward into entire sectors.
Food manufacturers start to see shifts in purchasing patterns. Restaurants notice changes in portion sizes and repeat visits. Retailers observe different basket compositions. Even categories that depend on impulse behavior—late-night ordering, convenience store purchases, fast-food runs—start to feel friction.
And the effects are not linear.
Small reductions in individual consumption can translate into large aggregate declines when multiplied across millions of people. A few hundred fewer calories per day per person becomes billions of calories not consumed across a population. That, in turn, becomes billions of dollars not spent in the same way as before.
What makes this particularly disruptive is that it is not driven by regulation, taxation, or cultural change.
It is driven by biology.
People are not consciously deciding to boycott junk food. They are simply less interested in it. The demand curve shifts without a campaign, without a policy, without a coordinated movement.
And that is what makes it powerful.
Because once consumption patterns begin to change at the level of instinct, the economy has no choice but to follow.
The Industries That Lose When People Eat Less
For decades, the food and beverage industry has operated on a simple, brutally effective model: increase consumption.
Bigger portions. More frequent snacking. Highly engineered foods designed to be irresistible. Entire business models have been built on maximizing how often people eat, how much they eat, and how little thought goes into either.
GLP-1 drugs cut directly across that logic.
When people eat less, the first impact is not abstract—it shows up in revenue.
Analysts at JPMorgan Chase have already projected that widespread adoption of these drugs could reduce U.S. food and beverage spending by tens of billions of dollars in the early 2030s. That is not a niche adjustment. That is a structural shift in demand.
And the pressure is not evenly distributed.
The most exposed companies are those built on high-frequency, low-cost consumption—fast food chains, processed snack brands, sugary beverages. These businesses rely on repetition. They depend on customers coming back again and again, often driven by habit rather than hunger.
GLP-1 drugs weaken that loop.
Early data suggests that people taking these medications don’t just eat less—they eat differently. There are indications that preferences shift away from salty, fatty, highly processed foods. The kinds of products that dominate convenience stores and fast-food menus become less appealing, not through moral effort, but through altered appetite.
That is a dangerous trend if your business is built on exactly those products.
Consider the implications for a company like McDonald’s. One analysis estimates that reduced demand driven by GLP-1 adoption could translate into tens of millions fewer customer visits annually, with corresponding revenue losses in the hundreds of millions of dollars.
On its own, that might not sound catastrophic. But layered across multiple brands, categories, and years, it becomes something more serious—a gradual erosion of the consumption patterns these companies depend on.
And yet, the story is not purely one of decline.
Because while people eat less, they do not stop eating altogether. Consumption doesn’t disappear—it shifts.
Some consumers may move toward smaller portions but higher-quality food. Others may substitute frequency for selectivity—eating out less often, but choosing differently when they do. Entire product categories could be reconfigured around lower calorie density, higher satiety, or simply different sensory profiles.
In other words, this is not just destruction. It is reallocation.
But that does not make it less disruptive.
Industries built on excess consumption do not adapt overnight. Supply chains, pricing strategies, product design, and marketing ecosystems are all tuned to a world where “more” is the default.
GLP-1 drugs introduce a population that increasingly defaults to “less.”
And for companies that have spent decades perfecting the art of getting people to eat more, that shift is not just inconvenient.
It is existential.
Beyond Food: Alcohol, Nicotine, and Addiction
If the story ended with food, GLP-1 drugs would already be disruptive enough.
But the early evidence suggests something broader is happening.
Because appetite is not limited to calories. The same systems in the brain that regulate hunger are deeply entangled with reward, impulse, and craving more generally. Food, alcohol, nicotine—these are not separate categories in the brain. They are variations of the same underlying circuitry.
And GLP-1 drugs appear to be interfering with that circuitry.
Some of the earliest signals came from unexpected places. In animal studies published in journals like The Lancet, researchers observed reduced alcohol consumption in test subjects after administering GLP-1-related treatments. That alone was intriguing, but not definitive.
More compelling are the human correlations that followed.
Studies tracking patients with type 2 diabetes found that those taking GLP-1 drugs were significantly less likely to develop patterns of substance dependence. Lower rates of alcohol abuse. Reduced likelihood of nicotine addiction. Even a measurable decline in opioid-related issues.
These are not small categories.
Alcohol, tobacco, and opioids represent entire industries—and entire public health crises. Each one is sustained not just by access, but by repeated, reinforced behavior. Craving leads to consumption. Consumption reinforces craving. The loop sustains itself.
GLP-1 drugs appear to weaken that loop.
Not by imposing discipline, but by reducing the intensity of the urge itself.
Patients often describe a subtle but noticeable shift. The habitual glass of wine feels less compelling. The cigarette is easier to skip. The constant background pull toward indulgence—whether food or otherwise—loses some of its grip.
It is important to be careful here. Correlation is not causation, and the research is still developing. These effects are not yet fully understood, nor are they guaranteed across all populations.
But the direction of travel is clear enough to raise serious questions.
Because if these drugs are not just suppressing appetite, but dampening broader reward-seeking behavior, then their impact extends far beyond weight loss.
They begin to touch the architecture of consumption itself.
An economy built on repeated indulgence—on habits that are easy to start and hard to break—suddenly encounters a population that finds those habits less compelling.
Less drinking. Less smoking. Less compulsive consumption.
At scale, that is not just a health story.
It is a behavioral shift with economic consequences that are difficult to fully map, but impossible to ignore.
And once again, it raises the same question from a different angle.
What happens to entire industries when people simply want less?
A Healthier Population Is a Richer Economy
There is a reason economists are paying attention to a drug that, on the surface, looks like a medical breakthrough.
Because poor health is not just a personal burden. It is an economic one.
When large portions of a population are unhealthy, the costs don’t stay confined to hospitals. They spill into productivity, labor participation, public spending, and long-term growth. People take more sick days. They work less efficiently. They retire earlier. In some cases, they leave the workforce altogether.
Multiply that across millions of people, and the drag becomes structural.
In the United States, the economic footprint of obesity-related conditions is enormous. Healthcare spending tied to diseases like diabetes, heart failure, and cardiovascular complications runs into hundreds of billions of dollars every year. These are not marginal expenses—they are embedded into the system.
GLP-1 drugs introduce the possibility of reducing that burden at scale.
If fewer people develop obesity-related conditions, healthcare systems spend less on managing chronic disease. That alone is significant. But the second-order effects are arguably more important.
Healthier individuals are more productive. They are more likely to remain employed. They require less care from others. They contribute more consistently over longer periods of time.
From an economic perspective, this compounds.
Some estimates suggest that improvements in population health driven by widespread GLP-1 adoption could meaningfully reduce healthcare costs while simultaneously increasing economic output. Even modest improvements—fractions of a percentage point in GDP—translate into massive absolute gains in large economies.
And then there are the unexpected effects.
When millions of people lose weight, even small physical changes aggregate into measurable outcomes. Lighter passengers mean marginally lower fuel consumption for airlines. Fewer obesity-related complications mean lower insurance payouts. Entire cost structures begin to shift, not dramatically at first, but persistently over time.
This is the quiet power of scale.
A single individual losing weight changes very little. A population doing so changes the economics of entire systems.
But there is a tension embedded in all of this.
Because while the benefits are broadly distributed—lower costs, higher productivity, better health—the access to those benefits is not.
And that is where the story begins to turn.
The Hidden Constraint: Who Can Actually Afford It
Up to this point, the story has been almost too clean.
A drug that works. A population that gets healthier. An economy that becomes more productive.
But this is where the friction begins.
Because none of those outcomes matter if the people who need the drug cannot get it.
The primary constraint is not scientific. It is financial.
GLP-1 drugs are expensive. In the United States, the annual cost of treatment can run into thousands of dollars per patient. And unlike a one-time intervention, this is not something you take and move on from. The effects are sustained only as long as the drug is used. When patients stop, weight often returns.
In practical terms, this turns the treatment into a recurring cost—something closer to a subscription than a cure.
That immediately narrows the pool of people who can realistically access it.
Public health systems, which might otherwise expand access, face a different problem. The scale of potential demand is simply too large. If even a fraction of the eligible population were to receive these drugs at current prices, the cost to governments would be staggering.
Private insurance does not fully solve the problem either.
Coverage is inconsistent and often restricted. In many cases, these drugs are reimbursed only when prescribed for conditions like type 2 diabetes, not for weight loss alone. That distinction matters, because it excludes a large portion of the population who would benefit from the treatment but do not meet the specific criteria required for coverage.
The result is a familiar pattern.
A breakthrough exists, but access to it is uneven.
And the unevenness is not random. It follows income, employment, and geography. Those with better insurance, higher incomes, or more flexible financial situations are more likely to benefit. Those without are left with the same environment, the same constraints, and the same limited set of options as before.
This is where the narrative shifts.
The question is no longer whether these drugs work.
The question is who gets to live in the world where they do.
The Economics of a Miracle Drug
The high cost of GLP-1 drugs is not an accident.
It is the result of how modern pharmaceutical markets are designed.
At the center of it is the patent system. Companies like Novo Nordisk and Eli Lilly hold exclusive rights over the production and sale of their drugs for a fixed period. That exclusivity allows them to set prices far above the cost of manufacturing, in order to recover research investments and generate profit.
In theory, this system incentivizes innovation.
In practice, it also creates temporary monopolies.
For drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, that monopoly is still intact in most major markets. Which means prices remain high—not because they have to be, but because they can be.
And when you combine high prices with massive demand, the numbers become almost absurd.
If a significant portion of the obese population were to take these drugs at current prices, the total cost would run into hundreds of billions—potentially even trillions—of dollars annually. Even after accounting for the savings from reduced healthcare spending, the net burden on public finances would still be enormous.
This is why governments have been cautious.
Expanding coverage sounds reasonable in principle. But at scale, it becomes fiscally destabilizing. Public health systems are not designed to fund long-term treatments for tens of millions of people at premium pharmaceutical prices.
So access remains restricted—not because the drugs lack value, but because they are too valuable at their current cost.
There is, however, a timeline to this.
Patents do not last forever.
As they expire, generic manufacturers enter the market, competition increases, and prices fall. In some countries, this process is already beginning. In others, particularly large Western markets, it is still years away.
Until then, pricing remains artificially elevated.
There are signs of adjustment. Policy pressure, negotiated pricing, and new delivery formats—such as oral versions of these drugs—are beginning to push costs downward at the margins. But these are incremental changes, not structural ones.
The core dynamic remains intact.
A highly effective treatment exists. Demand is enormous. Supply is controlled. Prices are high.
And in that environment, access is not determined by need.
It is determined by ability to pay.
Which means the economic structure surrounding these drugs is doing exactly what it was designed to do—maximize returns on innovation.
But in doing so, it is also shaping who benefits from that innovation in the first place.
Ozempic for the Rich
At this point, the pattern should feel familiar.
A breakthrough emerges. It promises to solve a widespread problem. The benefits are real, measurable, and potentially transformative.
And yet, access follows wealth.
Obesity is not evenly distributed across society. It is strongly correlated with income, time, and environment. People with lower incomes are more likely to live in areas where healthy food is expensive or inaccessible. They are more likely to work jobs that leave little time or energy for exercise. They are more exposed to cheap, high-calorie food and the marketing that promotes it.
In other words, the people most affected by obesity are often the least equipped to escape it.
GLP-1 drugs do not break that pattern.
If anything, they risk reinforcing it.
Because when access is limited by price, the first people to benefit are those who can afford to pay out of pocket or have comprehensive insurance coverage. They gain access to a tool that makes weight loss significantly more achievable—something that remains out of reach for others facing the same structural constraints.
This creates a divergence.
One group begins to lose weight more easily, improve health outcomes, and potentially benefit from the economic and social advantages that come with better health. Another group continues to operate within the same environment, relying on willpower, time, and resources they may not have.
Over time, that gap compounds.
Health differences become income differences. Income differences reinforce health differences. What begins as unequal access to a drug evolves into a broader form of inequality—one that is biological, economic, and social all at once.
This is what makes the situation uncomfortable.
Because it challenges a common narrative about innovation.
We like to believe that breakthroughs eventually benefit everyone. That technologies diffuse, prices fall, and access expands until the benefits are widely shared. And historically, that has often been true.
But timing matters.
The period between innovation and widespread accessibility can last years, sometimes decades. And during that window, the advantages are concentrated.
GLP-1 drugs appear to be entering that phase now.
For the foreseeable future, they are not a universal solution to obesity. They are a selective one.
Which means the world they create is not simply healthier.
It is unevenly healthier.
Treating the Symptom, Not the System
At this point, it is tempting to frame GLP-1 drugs as the solution.
They work. They scale. They reduce weight, improve health, and potentially ease the economic burden of obesity. By almost every measurable standard, they are a success.
But they do not change the system that made them necessary.
The environment John lives in still exists.
The same cheap, highly processed foods dominate store shelves. The same advertising machinery continues to push calorie-dense products into daily life. The same economic pressures make convenience more accessible than nutrition. Time remains scarce. Energy remains limited. Healthy living remains, in many cases, structurally inconvenient.
None of that disappears because a drug suppresses appetite.
GLP-1s operate downstream of the problem.
They intervene after the conditions that produce obesity have already taken hold. They help individuals navigate an unhealthy environment more successfully, but they do not make that environment any healthier.
In that sense, they are not a replacement for systemic change.
They are a workaround.
And like most workarounds, they come with trade-offs.
Instead of addressing food systems, pricing structures, urban design, or labor conditions, the solution becomes pharmacological. Instead of asking why unhealthy choices are so pervasive, the focus shifts to helping people resist them more effectively—through chemistry rather than structural reform.
That is not necessarily wrong.
There is a strong argument for using whatever tools are available to improve outcomes. If a drug can reduce suffering and extend healthy life, it has value regardless of the system it exists within.
But it does raise a deeper question.
Are we solving the problem, or are we adapting to it?
Because there is a difference between a society that makes healthy living easier, and a society that makes unhealthy living manageable through medication.
The former changes the conditions. The latter manages the consequences.
Right now, GLP-1 drugs sit firmly in the second category.
They do not reduce the production of cheap, addictive food. They do not change the incentives of companies that profit from overconsumption. They do not address the socioeconomic factors that shape diet and behavior at scale.
They simply make it easier to live within that system without bearing its full cost.
And for many people, that will be enough.
But it also means that the underlying dynamics remain intact.
The same forces that created the problem continue to operate—quietly, persistently, and at scale—while the solution is applied at the level of the individual.
Which leaves one final question.
What happens when this model expands?
The Post-Ozempic World
If GLP-1 drugs continue on their current trajectory, the future they point toward is not difficult to imagine.
But it is not singular.
There are, broadly speaking, two versions of a post-Ozempic world—and they diverge in ways that matter.
In the first, the optimistic version, prices fall.
Patents expire. Generic competitors enter the market. Governments negotiate better terms. Access expands beyond the wealthy and into the broader population. Over time, what begins as a premium treatment becomes a standard one.
In that world, the effects compound in a positive direction.
Obesity rates decline across income groups. Healthcare systems begin to see meaningful relief. Productivity improves. The burden of chronic disease eases. The economic gains are not just theoretical—they are felt in public finances, labor markets, and everyday life.
Consumption patterns shift, but industries adapt. Food companies reformulate products. Portion sizes adjust. New categories emerge that align with a lower-calorie baseline rather than fighting against it.
The system evolves.
But there is a second version.
In this one, access remains constrained.
Prices fall slowly, but not enough. Coverage expands, but unevenly. The drugs remain available, but primarily to those who can afford them—either directly or through better insurance.
And in that world, the consequences look very different.
Health becomes increasingly stratified. Higher-income populations get thinner, healthier, and more productive. Lower-income populations remain exposed to the same environmental pressures, with limited access to the tools that could offset them.
The gap widens—not just in income, but in physical health itself.
Obesity, which is already correlated with inequality, becomes even more tightly linked to it. What was once a shared public health issue begins to split along class lines. The visible markers of health—body weight, energy levels, long-term outcomes—start to reflect underlying economic divisions more clearly than before.
And the system that produced those divisions remains largely unchanged.
In both scenarios, the drugs work.
That is no longer the question.
The real question is what kind of society forms around them.
One that uses innovation to level the playing field.
Or one that uses it to quietly redraw the lines.
Conclusion
Ozempic does something rare.
It works in a world where most solutions have quietly failed.
For decades, the fight against obesity has been framed as a matter of personal responsibility. Eat better. Move more. Try harder. And yet, the broader trend has moved in the opposite direction. Not because people stopped caring, but because the system they operate within makes failure more likely than success.
GLP-1 drugs disrupt that dynamic.
They make weight loss achievable without requiring constant resistance against biology and environment. They reduce appetite, quiet cravings, and change behavior at the level where most interventions struggle to reach.
In doing so, they unlock something powerful.
A population that is healthier, more productive, and less burdened by chronic disease.
But they also expose something uncomfortable.
Because the same system that made obesity widespread is still intact. The same incentives that promote overconsumption continue to operate. And the same economic structures that limit access to better outcomes now determine who benefits from this breakthrough.
So the question is not whether Ozempic works. It does.
The question is what we choose to do with it.
Whether we allow it to become a tool that quietly reinforces inequality—offering relief to those who can afford it while leaving others behind.
Or whether it becomes part of a broader shift—one that not only treats the consequences of unhealthy systems, but begins to change those systems themselves.
Because in the end, Ozempic is not just a drug.
It is a lens.
Through it, you can see how modern societies solve problems—not by removing the conditions that create them, but by engineering ways to live with them more comfortably.
And that may be the most important implication of all.
Not what it does to our bodies.
But what it reveals about the world we’ve built.